Rate My Professor Philip Greenberg

Philip Greenberg, MD, is a distinguished professor of medicine, hematology-oncology, and immunology at the University of Washington and head of the Program in Immunology in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center, where he holds the Rona Jaffe Foundation Endowed Chair. He earned an AB in Biology from Washington University in St. Louis, Missouri, and an MD summa cum laude from the State University of New York Downstate Medical Center in 1971. His training includes an internship and residency in medicine and a postdoctoral fellowship in immunology at the University of California, San Diego, followed by a clinical and research fellowship in oncology at Fred Hutchinson Cancer Center. Joining Fred Hutch and the University of Washington Division of Oncology in 1976, Greenberg was a founding member of both the UW Department of Immunology and the Fred Hutch Program in Immunology. His research in Biology centers on cancer immunotherapy, particularly adoptive T-cell therapies. He was among the first to demonstrate that T cells recognize and eliminate malignant cells and that adoptive transfer of antigen-specific T cells can eradicate disseminated cancer. In 1981, his group showed that tumor antigen-specific CD4+ T cells provide help to CD8+ T cells for tumor eradication, a paper republished as a Pillar of Immunology. In the early 1990s, they pioneered collecting, expanding, and reinfusing patient T cells for therapy, including donor-derived CMV-specific CD8+ T cell clones to protect immunocompromised patients post-hematopoietic cell transplantation, as detailed in a 1995 New England Journal of Medicine paper cited over 2,300 times.